Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISRADIPINE vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Hypertension,Chronic stable angina
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Hepatic metabolism via CYP3A4 isoenzyme; undergoes extensive first-pass metabolism.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
96%, primarily to alpha-1-acid glycoprotein and albumin.
92-98% bound to plasma proteins (primarily albumin)
2.9 L/kg (3-5 L/kg reported); clinical meaning: extensive tissue distribution, high affinity for vascular smooth muscle.
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral: 15-24% (first-pass effect); sustained-release: approximately 30% due to reduced presystemic metabolism.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No dose adjustment required for mild to moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), initiate at 2.5 mg twice daily and titrate cautiously.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
For Child-Pugh Class A or B: initiate at 2.5 mg twice daily and titrate cautiously. For Child-Pugh Class C: use isradipine with caution; consider starting at 2.5 mg once daily and adjust based on response and tolerability.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not FDA-approved for pediatric use. Limited data: initial dose 0.05-0.15 mg/kg orally 3-4 times daily; maximum 0.8 mg/kg/day.
Not recommended for use in pediatric patients; safety and efficacy not established.
Initiate at 2.5 mg twice daily; titrate slowly due to increased risk of hypotension. Maximum dose usually 5 mg twice daily.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
None
No FDA black box warning.
May cause hypotension, peripheral edema, heart failure exacerbation (particularly in patients with pre-existing left ventricular dysfunction), and increased angina or myocardial infarction upon abrupt withdrawal. Use caution in patients with aortic stenosis, hepatic impairment, and in elderly patients. May cause gingival hyperplasia. Should be used with caution in patients with severe left ventricular dysfunction or heart failure.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Hypersensitivity to isradipine or any dihydropyridine calcium channel blocker; cardiogenic shock; unstable angina; acute myocardial infarction (within first 4 weeks); severe aortic stenosis; second- or third-degree AV block (unless pacemaker present); sick sinus syndrome (unless pacemaker present); concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) due to increased risk of toxicity.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase isradipine levels, leading to toxicity. High-fat meals may slow absorption but do not significantly alter overall effect. No other specific dietary restrictions.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
Isradipine is a pregnancy category C drug. In animal studies, it caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies) at doses 2-3 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk. First trimester: potential for teratogenic effects. Second and third trimesters: may cause fetal hypoxia, IUGR, and preterm delivery due to maternal hypotension; also associated with decreased uterine blood flow.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Isradipine is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.14. Low concentrations are expected; based on limited data, the relative infant dose is <1% of maternal weight-adjusted dose. However, due to potential for adverse effects in nursing infants (e.g., hypotension), caution is advised. Consider benefits of breastfeeding and importance of drug to mother.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
Pregnancy may alter the pharmacokinetics of isradipine due to increased plasma volume, renal clearance, and hepatic metabolism. No specific dose adjustment guidelines are established; however, higher doses may be required to achieve therapeutic effect. Conversely, increased sensitivity to hypotensive effects may necessitate dose reduction. Individualize dosing based on blood pressure response and tolerance. Start at low doses and titrate carefully.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
Isradipine is a dihydropyridine calcium channel blocker with high vascular selectivity; it causes less negative inotropic effect than nifedipine. It is used for hypertension and has been studied for Parkinson's disease but not FDA-approved for that indication. Its short half-life (8 hours) necessitates twice-daily dosing. Monitor for peripheral edema, headache, and dizziness. Avoid grapefruit juice as it increases drug levels. Use with caution in patients with aortic stenosis or heart failure with reduced ejection fraction.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take this medication exactly as prescribed, usually twice daily.,Do not drink grapefruit juice while taking isradipine.,Avoid sudden discontinuation; consult your doctor before stopping.,Common side effects include swelling of ankles/feet, headache, and dizziness; report severe or persistent symptoms.,This medicine does not cure hypertension but helps control it; continue taking even if you feel well.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
"The combination of isradipine, a dihydropyridine calcium channel blocker, with propranolol, a non-selective beta-blocker, can result in additive negative chronotropic and inotropic effects, leading to excessive bradycardia, hypotension, and potentially heart failure. Additionally, propranolol may mask the reflex tachycardia typically induced by isradipine's vasodilation, blunting compensatory mechanisms and increasing the risk of severe hypotension. Careful monitoring and dose adjustments are necessary when coadministering these agents."
"Isradipine, a calcium channel blocker, inhibits CYP3A4-mediated metabolism of saquinavir, a protease inhibitor used in HIV therapy. This leads to significantly increased saquinavir plasma concentrations, raising the risk of dose-related toxicities such as hepatotoxicity, QT prolongation, and gastrointestinal disturbances. Conversely, saquinavir may also inhibit isradipine metabolism, potentially causing enhanced hypotensive effects and peripheral edema."
"Amphotericin B, a polyene antifungal, can cause hypokalemia and hypomagnesemia due to renal tubular damage. Isradipine, a calcium channel blocker, may also affect electrolyte balance. Concomitant use increases the risk of severe hypokalemia, potentially leading to cardiac arrhythmias, QT prolongation, and neuromuscular effects. Close monitoring of serum electrolytes and ECG is essential."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISRADIPINE vs AFEDITAB CR, answered by our medical review team.
ISRADIPINE is a Calcium Channel Blocker that works by Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISRADIPINE and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISRADIPINE is: 2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISRADIPINE and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISRADIPINE is classified as Category C. Isradipine is a pregnancy category C drug. In animal studies, it caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies) at doses 2-3 times the maximum recomme. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.